G protein coupled receptor 17 antagonist - Myrobalan Therapeutics
Alternative Names: GPR17 antagonist - Myrobalan TherapeuticsLatest Information Update: 25 Sep 2024
At a glance
- Originator Myrobalan Therapeutics
- Class Antidementias; Antiparkinsonians; Eye disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis; Neuromyelitis optica; Parkinson's disease; Stroke
Most Recent Events
- 18 Sep 2024 Pharmacodynamics data from preclinical studies in Multiple sclerosis released by Myrobalan Therapeutics
- 10 Jan 2024 Preclinical trials in Alzheimer's disease in USA (PO) (Myrobalan Therapeutics pipeline, January 2024)
- 10 Jan 2024 Preclinical trials in Amyotrophic lateral sclerosis in USA (PO) (Myrobalan Therapeutics pipeline, January 2024)